Main Conference – Day 1Wednesday, 18 March 2026 - CET (Central European Time, GMT+01:00)

Chemically synthesized RNA oligonucleotides (oligos) have the potential of a powerful, multifaceted approach against cancer by acting as immune stimulators, RNA interference agents, and vaccines, as well as drug carriers. This presentation will first detail the simple chemical structure of RNA oligos that can be used for cancer vaccination. We will then introduce and discuss a new type of chemotherapeutic anticancer RNA oligo currently under development.

• Rapidly growing therapeutic oligonucleotide demand for indications with large patient populations require innovative manufacturing solutions. Answering the call for a more scalable and sustainable process, Codexis introduced the ECO Synthesis® Manufacturing Platform — a fully aqueous, enzymatic high yielding production approach for safe, quality, and efficacious siRNA. In this presentation, we will demonstrate the scalability of ECO Synthesis while illustrating the ability to transition from research to manufacturing scale and cGMP production, highlighting its potential to exceed productivity of traditional SPOS.
• Robust in-process control (IPC) testing is critical to achieving consistent product quality and purity in oligonucleotide manufacturing. Conventional solid-phase oligonucleotide synthesis (SPOS) presents IPC testing limitations due to the closed reaction environment and resin-bound intermediates. This platform, ECO Synthesis, enables early detection of process performance and/or deviations, and the opportunity for closed loop adjustment of reaction parameters in the future, resulting in high standards of API product quality, ensuring patient safety.

• Dysregulated mRNA processing has been identified as a new and druggable molecular hallmark of aging. Age-related changes in splicing factor expression disrupt physiological homeostasis, leading to loss of transcriptomic resilience, cellular senescence, and chronic diseases

• An antisense oligonucleotide approach has been developed to restore splicing regulator expression specifically in senescent cells. This method leverages endogenous autoregulation to achieve physiologically regulated expression of target genes within their normal homeostasis.

• Enabling pharmacokinetic (PK) properties and proof of principle for transcriptomic reprogramming of senescence have been demonstrated in an aged mouse model via an inhalation route.

• Initial applications of this technology target Idiopathic Pulmonary Fibrosis (IPF), a sentinel disease driven by senescence. Results show the ablation of harmful senescent properties in diseased cells and precision-cut lung slices (PCLS) from IPF patients, along with significant reductions in markers of inflammation and fibrosis

.• The approach has shown efficacy in senescent primary human cells across multiple cell lineages, suggesting potential applications for the treatment of various age-related diseases beyond respiratory conditions.